Your Ultimate FTSE 100 4-Stock Balanced Portfolio: SSE PLC, AstraZeneca plc, Banco Santander SA & Unilever plc

SSE PLC (LON:SSE), AstraZeneca plc (LON:AZN), Banco Santander SA (LON:BNC) and Unilever plc (LON:ULVR) provide a potent mix of income and capital growth potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

city

Sometimes it’s tough to strike the right balance between growth and income. Indeed, most investors tend to focus on one or the other, as opposed to creating a portfolio that provides them with a decent income while also having the potential to post impressive capital gains.

With that in mind, here are four stocks that, together, offer impressive dividends as well as exciting future prospects.

SSE

As far as income plays go, few stocks in the FTSE 100 can match SSE (LSE: SSE). That’s because it currently yields a hugely impressive 6% and, better still, dividends per share are all set to rise by at least the inflation rate over the medium term.

This may not sound like such an appealing option when inflation is less than 2%. However, with the scale of quantitative easing having the potential to push the inflation rate much higher over the medium term, SSE’s planned dividend increases could become a real asset. Indeed, they could help to maintain your income levels in real terms moving forward.

AstraZeneca

While also offering a respectable yield of 3.6%, AstraZeneca (LSE: AZN) comes with huge capital growth potential. That’s because its drugs pipeline is undergoing nothing short of a transformation right now.

Certainly, the company’s bottom line is due to be hit by continued fallout from the current patent cliff, with earnings forecast to fall by 13% this year and by 6% next year. However, looking beyond that, numerous acquisitions have made AstraZeneca’s pipeline a hot ticket. Indeed, further bids from global rivals are a very real possibility, which would clearly be good news for shareholders.

Banco Santander

Few companies offer the potent mix of income and growth that Santander (LSE: BNC) does. It currently yields a whopping 7.4% and offers huge growth potential. For instance, earnings per share (EPS) are due to increase by 23% in the current year and by 21% next year. This is well ahead of the market average and shows that Santander is a true growth play.

Of course, investors are being asked to pay a premium for such strong growth potential, with shares in Santander currently trading on a price to earnings (P/E) ratio of 15.6. This is much higher than the FTSE 100’s P/E of 13.8. However, when Santander’s growth forecasts are taken into account, it equates to a price to earnings growth (PEG) ratio of just 0.6, which shows that for the level of growth on offer, Santander trades at a reasonable price.

Unilever

With a yield of 3.3% and forecast growth in earnings of 9% next year, Unilever (LSE: ULVR) seems to strike the right balance between growth and income. Indeed, the consumer goods play seems to have a very bright future ahead of it.

For instance, customer loyalty in its brands is constantly increasing in the developing world, where Unilever has invested vast amounts of time and money to ensure the long term growth of its products. This exposure (emerging markets account for over half of Unilever’s revenue) could prove to be highly beneficial for investors moving forward, as greater wealth and consumer spending are anticipated across the developing world. As a result, shares in the company could deliver impressive gains over the medium term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and SSE. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »